Rezolsta
·
- Prescription status not stated
- Antibiotics, antivirals and antifungals taken into the body
- Active substance
- Darunavir;cobicistat
- Made by
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Rezolsta is indicated, in combination with other antiretroviral medicinal products, for the treatment of human immunodeficiency virus 1 (HIV 1) infection in adults and paediatric patients (aged 6 years and older, weighing at least 25 kg). Genotypic testing should guide the use of Rezolsta.
From the official label · 2026-09-30 · European Medicines Agency
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
SpainNo exact match for this strength and form
CanadaNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
Details
| Made by | |
|---|---|
| Active substance | Darunavir;cobicistat |
| Used in | Antibiotics, antivirals and antifungals taken into the body |
| Classification | J05AR14 · Antibiotics, antivirals and antifungals taken into the body |
| Authorised on | 2014-11-19 |
| Last updated by the regulator | 2026-09-08 |
| EMA product number | EMEA/H/C/002819 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).